LERCANIDIPINE HYDROCHLORIDE
It is a new long-acting dihydropyridine Calcium Channel Blocker (CCB) which selectively inhibits the influx of extracellular calcium through voltage-gated calcium channels.Mild to moderate hypertension.
Initially 10mg once daily, increased, if necessary, after at least 2 weeks to 20mg daily.
Aortic stenosis, unstable angina, uncontrolled heart failure within 1 month of myocardial infarction, pregnancy and breast-feeding.
In hepatic and renal impairment, left ventricular dysfunction, sick sinus syndrome (if pacemaker not fitted), avoid grape fruit juice (may affect metabolism).
Flusing, peripheral oedema, palpitation, tachycardia, headache, dizziness, asthenia, G.I.distrubance, hypotension, drowsiness, myalgia, polyuria, rash.
No notable drug interactions observed, cytochrome P-450 3A4 inhibitor (itraconazole) may alter the pharmacokinetics of lercanidipine.